Besixin

Besixin0.6%

Ophthalmic Suspension

Besifloxacin

Opso Saline Ltd.

Product Code : 2083
MRP 351.06
10% Off
Best PriceTk
/
1
Section

Medicine overview

Indications of Besixin 0.6%

Besixin 0.6% ophthalmic suspension is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Corynebacterium pseudodiphtheriticum Corynebacterium striatum Haemophilus influenzae Moraxella lacunata Staphylococcus aureus ... Read moreBesixin 0.6% ophthalmic suspension is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Corynebacterium pseudodiphtheriticum Corynebacterium striatum Haemophilus influenzae Moraxella lacunata Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis Staphylococcus lugdunensis Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius Efficacy for this organism was studied in fewer than 10 infections.

Theropeutic Class

Ophthalmic antibacterial drugs

Pharmacology

Besixin 0.6% acts against Gram positive and Gram negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme required for replication, transcription and repair of bacterial DNA. Topoisomerase IV is an essential enzyme required for partitioning of the chromosomal DNA during bacterial cell division.

Dosage & Administration of Besixin 0.6%

Adults and children (1 year of age and older): Instill one drop in the affected eye(s) 3 times a day for 7 days.Pediatric Use: The safety and effectiveness of Besixin 0.6% in infants below one year of age have not been established.

Dosage of Besixin 0.6%

Adults and children (1 year of age and older): Instill one drop in the affected eye(s) 3 times a day for 7 days.Pediatric Use: The safety and effectiveness of Besixin 0.6% in infants below one year of age have not been established.

Interaction of Besixin 0.6%

No such information found. Topical ophthalmic use only

Contraindications

Hypersensitivity to the active ingredient or any component of this formulation.

Side Effects of Besixin 0.6%

The most frequently reported ocular adverse event was conjunctival redness, reported in approximately 2% of patients. Other adverse events reported in patients receiving Besixin 0.6% occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.

Pregnancy & Lactation

Pregnancy Category C. No adequate and well-controlled studies are established in pregnant women. This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: It is not known whether Besixin 0.6% is secreted in human milk or not. Caution should be exercised when Besixin 0.6% is administered to a nursing mother.

Precautions & Warnings

This drug is for topical ophthalmic use only and should not be injected subconjunctivally, nor should it be introduced directly into the anterior chamber of the eye. As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. To prevent contamination do not touch the tip of the dropper to eye, eyelid or any surface of the affected eye. Patients should not wear contact lenses during the course of therapy with this drug. Shake well before use.

Overdose Effects of Besixin 0.6%

No data are available regarding the over dose of Besixin 0.6%.

Storage Conditions

Store in a cool, dry place and protected from light. Keep out of the reach of children. Discard the container 4 weeks after opening.

Drug Classes

Ophthalmic antibacterial drugs

Mode Of Action

Besixin 0.6% acts against Gram positive and Gram negative bacteria due to the inhibition of both bacterial DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme required for replication, transcription and repair of bacterial DNA. Topoisomerase IV is an essential enzyme required for partitioning of the chromosomal DNA during bacterial cell division.

Pregnancy

Pregnancy Category C. No adequate and well-controlled studies are established in pregnant women. This drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: It is not known whether Besixin 0.6% is secreted in human milk or not. Caution should be exercised when Besixin 0.6% is administered to a nursing mother.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.